Administration Should Withdraw Big Pharma-Backed Policies Like the Rebate Rule, Move Forward with Solutions to Stop Drug Companies’ Price Gouging
For Immediate Release
Contact: Jon Conradi
Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement Monday after Big Pharma scuttled a scheduled meeting on prescription drug prices between White House officials and executives representing major pharmaceutical companies.
“Big Pharma is acting like the White House works on their schedule,” said CSRxP executive director Lauren Aronson. “The American people are counting on the administration to stand up to Big Pharma and hold this industry accountable that hiked prices during a pandemic and now acts like it can call the shots.”
“The White House cannot allow pharmaceutical companies to exercise de facto veto power over solutions to hold the industry accountable, while advancing Pharma-backed ideas like the Rebate Rule that would hand drug companies a massive bailout,” Aronson continued. “The White House should withdraw its support for the Pharma-supported reboot of the Rebate Rule that would increase premiums on Medicare Part D beneficiaries, cost taxpayers more than $200 billion, hand Big Pharma a more than hundred-billion-dollar bailout and do nothing to lower prescription drug prices.”
Read more about the Big Pharma bailout, aka Rebate Rule HERE.
Learn more about market-based solutions to hold Big Pharma accountable and lower prescription drug prices HERE.